Arimidex Tablet
Product Images NDC 62559-670

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Arimidex (NDC 62559-670). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

A Kaplan-Meier survival curve chart showing disease-free survival over 90 months for patients treated with Anastrozole versus Tamoxifen. The y-axis represents proportion alive and disease-free, while the x-axis measures months of disease-free survival. The chart includes patient counts at risk over time for both treatments, with Anastrozole depicted by a dashed line and Tamoxifen by a solid line.*

FDA Label Image

Figure-2 (Figure 2)

A line graph depicting disease-free survival in months on the x-axis versus the proportion alive and disease-free on the y-axis. Two treatments are compared: Anastrozole (dashed line) and Tamoxifen (solid line). The graph shows patient counts at risk for each treatment at various time points.*

FDA Label Image

Ani (Ani 01)

FDA Label Image

Ani (Ani)

FDA Label Image

Chemical Structure For Anastrozole (Image 01)

Chemical structure of Anastrozole, the active ingredient in ARIMIDEX 1 mg oral tablets. The diagram shows the molecular arrangement including benzene ring with cyanide and methyl groups and an attached triazole ring.*

FDA Label Image

Image 02

Label for ARIMIDEX 1 mg anastrozole tablets, oral dosage form, containing 30 tablets. The label includes dosage strength, manufacturer ANI Pharmaceuticals, Inc., NDC 62559-670-30, storage instructions, and a barcode. It states Rx only and features a warning to keep out of reach of children.*

FDA Label Image

Figure 3 (Image 04)

A Kaplan-Meier survival curve comparing the proportion of event-free patients over time in months for two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The graph includes a risk table below showing numbers of patients at risk for each treatment group at various time points up to 120 months.*

FDA Label Image

Figure 4 (Image 05)

A Kaplan-Meier curve graph comparing the proportion event-free over time (in months) between patients treated with Anastrozole and Tamoxifen. The solid line represents Anastrozole, and the dashed line represents Tamoxifen. Below the graph, the number of patients at risk is shown at various time points up to 120 months for each treatment group.*

FDA Label Image

Figure 5 (Image 06)

A Kaplan-Meier plot comparing time to progression in months versus the proportion of patients not progressing under randomized treatment with Anastrozole (solid line) and Tamoxifen (dashed line). The x-axis shows months up to 32, and the y-axis shows the proportion not progressing from 0 to 1. The number of patients at risk is provided below the x-axis for both treatments.*

FDA Label Image

Figure 6 (Image 07)

A Kaplan-Meier survival curve chart showing the proportion not progressing over time (in months) for two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The x-axis represents the time to progression in months up to 42 months, and the y-axis shows the proportion not progressing from 0.0 to 1.0. A table below indicates the number of subjects at risk at various time points for each treatment group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.